Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/32859
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRozov, Tatiana [UNIFESP]
dc.contributor.authorOliveira, Viviane Ziebell de
dc.contributor.authorSantana, Maria Angelica
dc.contributor.authorAdde, Fabiola Villac
dc.contributor.authorMendes, Rita Heloisa
dc.contributor.authorPaschoal, Ilma Aparecida
dc.contributor.authorCaldeira Reis, Francisco J.
dc.contributor.authorShinzato Higa, Laurinda Yoko
dc.contributor.authorCastro Toledo, Antonio Carlos de
dc.contributor.authorPahl, Marcia
dc.contributor.authorPulmozyme Study Grp
dc.date.accessioned2016-01-24T14:05:24Z-
dc.date.available2016-01-24T14:05:24Z-
dc.date.issued2010-09-01
dc.identifierhttp://dx.doi.org/10.1002/ppul.21267
dc.identifier.citationPediatric Pulmonology. Hoboken: Wiley-liss, v. 45, n. 9, p. 874-882, 2010.
dc.identifier.issn8755-6863
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/32859-
dc.description.abstractBackground: Health-related quality of life (HRQOL) measurements provide valuable information about the psychological and social impact of treatment on patients with cystic fibrosis (CF). This study evaluated the HRQOL of Brazilian patients with CF and assessed the changes in HRQOL domains over 1 year after dornase alfa (Pulmozyme) introduction.Patients and Methods: One hundred fifty-six stable patients with CF and 89 caregivers answered the Portuguese-validated version of the Cystic Fibrosis Questionnaire-Revised (CFQ-R) at baseline (T(0)), and at 3 (T(1)), 6 (T(2)), 9 (T(3)), and 12 (T(4)) months of follow-up. Eighteen patients were excluded because they did not fulfill the inclusion criteria. the patients were analyzed in two groups: those aged 6-11 years and those aged 14 years and older. ANOVA for observed repeated results and the last observation carried forward (LOCF) method for missing data were used for the statistical analysis.Results: After 1 year of follow-up, there was significant improvement in respiratory symptoms (T(4) - T(0) = 8.1; 95% confidence interval (95% CI) = [2.1;14.0]; effect size (ES) = 0.35; P<0.001), Emotional Functioning (T(4) - T(0) = 5.6; 95% CI = [1.1;10.1]; ES = 0.31; P<0.05), Social Functioning (T(4) - T(0) = 6.0; 95% CI = [1.3;11.7]; ES = 0.31; P<0.05), Body Image (T(4) - T(0) = 11.9; 95% CI = [4.1;19.7]; ES = 0.42; P<0.05), and Treatment Burden (T(4) - T(0) = 5.3; 95% CI = [0.3;10.3]; ES = 0.24; P<0.05) domains in the younger group. A significant improvement in Role Functioning (T(4) - T(0) = 6.1; 95% CI = [1.1;11.1]; ES = 0.40; P<0.05), Body Image (T(4) - T(0) = 12.6; 95% CI = [3.5;21.7]; ES = 0.46; P<0.05), and Weight (T(4) - T(0) = 11.7; 95% CI = [1.8;21.6]; ES = 0.40; P<0.05) was obtained in the older group. the caregivers' CFQ-R showed improvements in the Digestive Symptoms (T(4) - T(0) = 5.5; 95% CI = [1.5;9.4]; ES = 0.30; P<0.05), Respiratory Symptoms (T(4) - T(0) = 7.6; 95% CI = [3.9;11.4]; ES = 0.48; P< 0.05), and Weight (T(4) - T(0) = 10.1; 95% CI = [1.6;18.6]; ES = 0.26; P<0.05) domains.Conclusion: the introduction of dornase alfa improved the HRQL of the patients with CF during the first year of treatment. Pediatr Pulmonol. 2010; 45:874-882. (C) 2010 Wiley-Liss, Inc.en
dc.description.sponsorshipRoche, Brazil
dc.format.extent874-882
dc.language.isoeng
dc.publisherWiley-Blackwell
dc.relation.ispartofPediatric Pulmonology
dc.rightsAcesso restrito
dc.subjectcystic fibrosisen
dc.subjectrhDNaseen
dc.subjectquality of lifeen
dc.subjecttreatmenten
dc.titleDornase Alfa Improves the Health-Related Quality of Life Among Brazilian Patients With Cystic Fibrosis-A One-Year Prospective Studyen
dc.typeArtigo
dc.rights.licensehttp://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade Federal do Pará (UFPA)
dc.contributor.institutionHEOM
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionCGP
dc.contributor.institutionFiocruz MS
dc.contributor.institutionUNIFENAS BH
dc.contributor.institutionRoche Brasil
dc.description.affiliationUNIFESP EPM, São Paulo, Brazil
dc.description.affiliationUFPA, HCPA, Porto Alegre, RS, Brazil
dc.description.affiliationHEOM, Salvador, BA, Brazil
dc.description.affiliationICr HC FMUSP, São Paulo, Brazil
dc.description.affiliationUNICAMP Adults, FCM, Campinas, SP, Brazil
dc.description.affiliationCGP, Belo Horizonte, MG, Brazil
dc.description.affiliationFiocruz MS, IFF, BR-21045900 Rio de Janeiro, Brazil
dc.description.affiliationUNIFENAS BH, Belo Horizonte, MG, Brazil
dc.description.affiliationRoche Brasil, São Paulo, Brazil
dc.description.affiliationUnifespUNIFESP EPM, São Paulo, Brazil
dc.identifier.doi10.1002/ppul.21267
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000281628700005
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.